Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.
INTRODUCTION In patients treated with lorlatinib after failure of a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), ALK mutations were identified as a potential marker of response. To identify other correlates, we evaluated ALK fusion subtypes and co-mutations to predict clinical out...